


Comparative metabolic and lipidomic profiling of human breast cancer cells with different metastatic potentials

SUPPLEMENTARY FIGURES AND TABLES


A

NL: 8.46E4




B

NL: 1.11E4




Supplementary Figure S1: Representative spectra of lipid profiles from mammary epithelial and breast cancer cells, derived from nano-electrospray mass spectrometry in A. positive ion mode and B. negative ion mode.

Compound #1




Compound #2




(Continued)

Compound #3




Compound #4




(Continued)

Compound #5




Compound #6




(Continued)

Compound #7




Compound #8




(Continued)

Compound #9




Compound #10




(Continued)

Compound #11




Compound #12




(Continued)

Compound #13




Compound #14




(Continued)

Compound #15




Compound #16




(Continued)

Compound #17




Compound #18




(Continued)

Compound #19




Compound #20




(Continued)

Compound #21




Compound #22




(Continued)

Compound #23




Compound #24




(Continued)

Compound #25




Compound #26




(Continued)

Compound #27




Compound #28



(Continued)


Compound #29

PS [C40:6 (18:0/22:6)] [M - H]⁻, m/z 834
 • C₃H₅NO₂ : serine




Compound #30

PS [C40:5 (18:1/22:4)] [M - H]⁻, m/z 836
 • C₃H₅NO₂ : serine




(Continued)

Compound #31




Compound #32




(Continued)

Compound #33




Compound #34




(Continued)

Compound #35




Compound #36




(Continued)

Compound #37




Compound #38




(Continued)

Compound #39




Compound #40




(Continued)

Compound #41




Compound #42




(Continued)

Compound #43



Compound #44



Supplementary Figure S2: MS/MS spectra of the assigned 44 intact lipids in mammary epithelial and breast cancer cells using LTQ-XL mass spectrometry. All lipids were identified by matching against the in-house MS/MS library, databases of Lipidmaps and LipidBlast, based on their major structural features, and the major precursor and fragment ions were indicated as red characters. Each compound corresponding to compound # was listed in Supplementary Table S2.

Supplementary Table S1: A GC-MS-based metabolic profile of breast cancer cells in different progression stages

No.	Compound	RT	MCF-10A	MCF-7	MDA-MB-231
Alcohol					
1	Erythritol	19.03 19.05	3.94 ± 0.75 ^a	14.55 ± 7.03 ^b	1.50 ± 0.27 ^a
2	Myo-inositol	28.95	130.11 ± 41.21 ^a	62.12 ± 28.52 ^a	242.86 ± 87.10 ^b
Amino acid					
3	Alanine	7.00	110.92 ± 49.66 ^{ab}	169.45 ± 56.46 ^a	74.36 ± 16.61 ^b
4	Asparagine	20.85	9.08 ± 2.84 ^a	15.92 ± 5.47 ^b	6.15 ± 1.27 ^a
5	Aspartic acid	15.06 17.41 17.43	119.17 ± 34.00 ^a	85.77 ± 42.08 ^{ab}	60.90 ± 13.09 ^b
6	Glutamine	19.78 19.79 19.81 23.11	343.20 ± 46.94 ^a	1401.87 ± 770.11 ^b	355.54 ± 45.65 ^a
7	Glycine	7.47 12.02 12.03	221.07 ± 47.07	315.14 ± 99.45	362.64 ± 138.97
8	Leucine	8.30 11.72	54.91 ± 7.33	101.75 ± 42.91	68.48 ± 24.12
9	Lysine	26.08	89.80 ± 18.56	150.53 ± 65.83	91.28 ± 26.41
10	Ornithine	24.00	5.09 ± 1.33 ^a	6.96 ± 2.16 ^a	17.80 ± 3.10 ^b
11	Proline	11.81	38.33 ± 11.90 ^a	112.39 ± 50.66 ^b	25.09 ± 8.62 ^a
12	Serine	10.81 13.45	43.61 ± 12.39 ^a	191.98 ± 104.09 ^b	38.99 ± 12.56 ^a
13	Threonine	11.74 11.75 14.08 14.09	39.35 ± 9.52 ^a	258.60 ± 80.39 ^b	33.90 ± 9.90 ^a
14	Tryptophan	30.92	25.12 ± 8.06 ^{ab}	42.38 ± 15.92 ^a	18.97 ± 5.16 ^b
15	Tyrosine	26.37	137.08 ± 34.37 ^a	389.82 ± 193.48 ^b	101.24 ± 15.73 ^a
16	Valine	6.71 9.74 9.76	98.82 ± 30.15 ^a	323.69 ± 105.30 ^b	78.92 ± 26.64 ^a

(Continued)

No.	Compound	RT	MCF-10A	MCF-7	MDA-MB-231
Fatty acid					
17	3-hydroxybutanoic acid	8.05	26.96 ± 6.97 ^a	22.64 ± 11.89 ^a	49.06 ± 12.80 ^b
18	Oleic acid	31.08	1.41 ± 0.71	1.68 ± 1.33	2.44 ± 0.60
19	Palmitic acid	28.36	13.73 ± 2.11 ^{ab}	12.54 ± 4.31 ^a	20.13 ± 7.57 ^b
20	Stearic acid	31.49	7.84 ± 3.60	8.26 ± 2.33	11.92 ± 3.58
Organic acid					
21	Isocitric acid	24.07	2.14 ± 0.76 ^a	12.26 ± 4.53 ^b	8.64 ± 3.01 ^b
22	Lactic acid	6.04	32.16 ± 7.87 ^a	199.70 ± 85.43 ^b	59.49 ± 23.99 ^a
23	Malic acid	16.67	7.74 ± 2.46 ^a	14.68 ± 4.87 ^b	5.10 ± 1.28 ^a
24	Oxalic acid	7.90	248.51 ± 94.00 ^a	388.76 ± 128.54 ^{ab}	509.14 ± 194.63 ^b
25	Pyruvic acid	7.63	11.16 ± 7.74	11.97 ± 4.66	15.44 ± 3.16
Purine					
26	Adenine	24.95	6.71 ± 1.03 ^a	8.28 ± 1.48 ^a	109.12 ± 13.81 ^b
27	Guanine	29.59	0.37 ± 0.06 ^a	116.02 ± 58.59 ^b	137.75 ± 18.65 ^b
28	Hypoxanthine	23.73	244.10 ± 92.38 ^a	167.28 ± 97.68 ^{ab}	84.17 ± 9.68 ^b
29	Inosine	36.11	11.30 ± 1.94 ^a	22.60 ± 11.00 ^b	2.34 ± 1.21 ^a
30	Uracil	12.86	22.51 ± 3.40 ^a	2.05 ± 0.76 ^b	29.13 ± 6.33 ^a
31	Xanthine	27.80	20.49 ± 6.32 ^a	0.23 ± 0.35 ^b	2.71 ± 0.74 ^b
Sugar					
32	6-phosphogluconic acid	33.93	4.58 ± 1.35	3.18 ± 2.67	4.61 ± 2.15
33	Fructose-6-phosphate	32.31	34.04 ± 13.35 ^a	5.94 ± 4.14 ^b	12.92 ± 3.98 ^b
34	Glucose	27.15	11.88 ± 8.37 ^{ab}	20.67 ± 12.67 ^a	7.15 ± 1.70 ^b
35	Glucose-6-phosphate	32.32	187.35 ± 36.35 ^a	41.77 ± 23.83 ^b	118.50 ± 30.10 ^c
		32.49			
		32.74			
		33.03			
		33.33			
		33.50			
36	Glyceric acid	12.67	0.94 ± 0.37 ^a	2.43 ± 0.99 ^b	0.92 ± 0.62 ^a
37	Mannose-6-phosphate	35.72	59.41 ± 18.13 ^a	17.48 ± 9.79 ^b	11.95 ± 3.52 ^b
38	Sucrose	36.96	6.20 ± 2.29	5.85 ± 0.90	8.06 ± 3.77
Other					
39	Creatinine	18.10	3.86 ± 2.02 ^a	14.50 ± 6.90 ^b	3.10 ± 1.48 ^a

Different letters in the same row indicate a significant difference. Mean ± SD value for quintuplicate measurements are shown. The values are multiplied by '10e3' due to significantly small values

Supplementary Table S2: Normalized ion intensities of identified lipids in mammary epithelial cells (MCF-10A) and metastatic breast cancer cells (MCF-7 and MDA-MB-231) using nano-electrospray mass spectrometry

No.	Lipid molecular species (total acyl carbons:total double bonds)	Proposed composition	Ion species	m/z	MCF-10A	MCF-7	MDA-MB-231
Positive ion mode							
Phosphatidylcholine (PC)							
1	PC 34:2	C16:1/C18:1	[M + H] ⁺	758	1.77 ± 0.26 ^a	3.52 ± 0.39 ^b	4.37 ± 1.07 ^b
2	PC 36:3	C18:1/C18:2	[M + H] ⁺	784	2.05 ± 0.42 ^a	4.93 ± 0.58 ^{ab}	8.42 ± 3.58 ^b
3	PC 36:2	C18:1/C18:1	[M + H] ⁺	786	9.72 ± 2.33 ^a	24.65 ± 2.90 ^{ab}	39.53 ± 15.19 ^b
4	PC 37:3	C18:3/C19:0	[M + H] ⁺	798	7.45 ± 5.28 ^a	10.67 ± 3.46 ^a	8.63 ± 0.97 ^a
5	PC 38:5	C18:2/C20:3	[M + H] ⁺	808	0.37 ± 0.12 ^a	1.19 ± 0.32 ^b	1.68 ± 0.75 ^b
6	PC 38:4	C18:0/C20:4	[M + H] ⁺	810	0.39 ± 0.05 ^a	0.63 ± 0.12 ^a	1.76 ± 0.27 ^b
7	PC 38:2	C18:1/C20:1	[M + H] ⁺	814	1.36 ± 0.22 ^a	2.54 ± 0.29 ^b	1.39 ± 0.23 ^a
8	PC 38:1	C18:1/C20:0	[M + H] ⁺	816	2.88 ± 0.49 ^a	4.52 ± 0.60 ^b	5.27 ± 0.83 ^b
9	PC 38:0	C18:0/C20:0	[M + H] ⁺	818	3.39 ± 1.63 ^a	5.11 ± 2.16 ^{ab}	7.73 ± 2.77 ^b
10	PC 40:6	C18:1/C22:5	[M + H] ⁺	834	1.33 ± 0.17 ^a	2.10 ± 0.19 ^b	2.03 ± 0.21 ^b
Plasmenylphosphatidylcholine (plasmenyl-PC)							
11	Plasmenyl-PC 38:1	C20:0/C18:1	[M + H] ⁺	800	3.87 ± 1.43 ^a	7.46 ± 0.64 ^b	3.67 ± 2.00 ^a
Plasmenylphosphatidylethanolamine (plasmenyl-PE)							
12	plasmenyl-PE 34:0	C18:0/C16:0	[M + H] ⁺	704	1.33 ± 0.49 ^a	1.98 ± 0.64 ^a	2.02 ± 0.32 ^a
Sphingomyelin (SM)							
13	SM 34:1	D18:1/16:0	[M] ⁺	703	2.07 ± 0.94 ^a	2.26 ± 0.92 ^a	3.10 ± 0.76 ^a
Negative ion mode							
Phosphatidylethanolamine (PE)							
14	PE 36:2	C18:1/C18:1	[M - H] ⁻	742	10.01 ± 0.69 ^a	16.17 ± 0.67 ^b	4.68 ± 0.30 ^c
15	PE 36:0	C17:0/C19:0	[M - H] ⁻	746	2.79 ± 0.57 ^a	7.30 ± 0.37 ^b	4.35 ± 1.37 ^c
16	PE 38:5	C18:1/C20:4	[M - H] ⁻	764	3.31 ± 0.27 ^a	8.87 ± 0.17 ^b	4.09 ± 0.62 ^c
17	PE 40:5	C18:1/C22:4	[M - H] ⁻	792	4.86 ± 0.36 ^a	8.11 ± 0.47 ^b	7.51 ± 1.27 ^b
Plasmenylphosphatidylethanolamine (plasmenyl-PE)							
18	plasmenyl-PE 38:4	C18:0/C20:4	[M - H] ⁻	750	4.55 ± 0.28 ^a	1.65 ± 0.18 ^b	13.03 ± 1.02 ^c
Phosphatidylserine (PS)							
19	PS 34:2	C16:1/C18:1	[M - H] ⁻	758	7.56 ± 0.72 ^a	15.01 ± 1.36 ^b	25.11 ± 4.40 ^c
20	PS 34:1	C16:0/C18:1	[M - H] ⁻	760	33.19 ± 4.34 ^a	48.96 ± 3.55 ^b	80.84 ± 12.65 ^c

(Continued)

No.	Lipid molecular species (total acyl carbons:total double bonds)	Proposed composition	Ion species	m/z	MCF-10A	MCF-7	MDA-MB-231
21	PS 34:0	C16:0/C18:0	[M - H] ⁻	762	9.76 ± 0.96 ^a	11.87 ± 0.82 ^a	20.15 ± 2.89 ^b
22	PS 35:1	C17:0/C18:1	[M - H] ⁻	774	5.22 ± 0.56 ^a	12.82 ± 1.34 ^b	6.31 ± 0.69 ^a
23	PS 36:3	C18:1/C18:2	[M - H] ⁻	784	10.54 ± 1.10 ^a	6.36 ± 0.63 ^a	34.69 ± 7.56 ^b
24	PS 36:2	C18:0/C18:2	[M - H] ⁻	786	36.71 ± 2.26 ^a	36.22 ± 3.41 ^a	77.96 ± 12.92 ^b
25	PS 36:1	C18:0/C18:1	[M - H] ⁻	788	51.25 ± 3.70 ^a	44.11 ± 2.35 ^a	104.38 ± 12.65 ^b
26	PS 36:0	C18:0/C18:0	[M - H] ⁻	790	11.46 ± 0.72 ^a	23.03 ± 0.96 ^b	24.21 ± 1.86 ^b
27	PS 38:4	C18:0/C20:4	[M - H] ⁻	810	2.70 ± 0.50 ^a	2.88 ± 0.18 ^a	11.97 ± 1.30 ^b
28	PS 38:1	C18:1/C20:0	[M - H] ⁻	816	7.29 ± 0.42 ^a	11.43 ± 0.52 ^b	10.23 ± 0.88 ^c
29	PS 40:6	C18:0/C22:6	[M - H] ⁻	834	2.91 ± 0.33 ^a	5.63 ± 0.55 ^b	12.13 ± 1.18 ^c
30	PS 40:5	C18:1/C22:4	[M - H] ⁻	836	5.35 ± 0.60 ^a	13.14 ± 0.75 ^b	12.88 ± 1.32 ^b
31	PS 40:4	C18:0/C22:4	[M - H] ⁻	838	2.82 ± 0.32 ^a	3.01 ± 0.26 ^a	10.62 ± 1.61 ^b
32	PS 40:2	C18:1/C22:1	[M - H] ⁻	842	5.38 ± 0.26 ^a	3.46 ± 0.06 ^b	5.76 ± 0.52 ^a
33	PS 40:1	C18:1/C22:0	[M - H] ⁻	844	9.54 ± 0.58 ^a	15.09 ± 0.72 ^b	13.10 ± 1.15 ^c
Phosphatidylinositol (PI)							
34	PI 32:1	C16:0/C16:1	[M - H] ⁻	807	2.22 ± 0.15 ^a	7.17 ± 0.29 ^a	37.76 ± 8.27 ^b
35	PI 34:2	C16:1/C18:1	[M - H] ⁻	833	5.50 ± 0.44 ^a	6.28 ± 0.43 ^a	11.56 ± 1.42 ^b
36	PI 34:1	C16:0/C18:1	[M - H] ⁻	835	9.49 ± 0.76 ^a	23.30 ± 1.44 ^b	13.32 ± 2.38 ^c
37	PI 36:2	C18:1/C18:1	[M - H] ⁻	861	27.51 ± 1.95 ^a	18.17 ± 1.25 ^b	6.75 ± 0.60 ^c
38	PI 36:1	C18:0/C18:1	[M - H] ⁻	863	21.06 ± 1.47 ^a	35.18 ± 2.23 ^b	3.39 ± 0.41 ^c
39	PI 38:6	C16:0/C22:6	[M - H] ⁻	881	2.02 ± 1.11 ^a	3.19 ± 0.36 ^a	7.73 ± 3.08 ^b
40	PI 38:5	C18:1/C20:4	[M - H] ⁻	883	1.63 ± 0.27 ^a	2.04 ± 0.19 ^a	6.89 ± 1.28 ^b
41	PI 38:4	C18:0/C20:4	[M - H] ⁻	885	10.73 ± 0.86 ^a	7.42 ± 0.57 ^a	62.18 ± 7.40 ^b
42	PI 38:3	C18:0/C20:3	[M - H] ⁻	887	11.90 ± 0.82 ^a	5.74 ± 0.49 ^b	13.90 ± 1.61 ^c
Phosphatidylglycerol (PG)							
43	PG 34:1	C16:0/C18:1	[M - H] ⁻	747	4.99 ± 0.61 ^a	8.17 ± 0.61 ^b	3.61 ± 0.95 ^c
44	PG 36:2	C18:1/C18:1	[M - H] ⁻	773	4.40 ± 0.61 ^a	8.90 ± 1.34 ^b	0.96 ± 0.27 ^c

^a Each value represents the mean ± standard deviation (SD) (n = 5).

^b For simplicity, '×10e1' and '×10e2' were omitted from the values of identified lipids in positive mode and negative mode, respectively.